[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Arya AK, El-Fert A, Devling T, Eccles RM, Aslam MA, Rubbi CP, Vlatković N, Fenwick J, Lloyd BH, Sibson DR, Jones TM, Boyd MT: Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br J Cancer; 2010 Jul 13;103(2):186-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53.
  • BACKGROUND: Primary radiotherapy (RT) is a mainstay of treatment for laryngeal squamous cell carcinoma (LSCC).
  • Moreover, RT is associated with debilitating early- and late-treatment-related toxicity, thus finding means to de-escalate therapy, while retaining/augmenting therapeutic effectiveness, is highly desirable. p53 is a key mediator of radiation responses; we therefore investigated whether Nutlin-3, a small-molecule inhibitor of MDM2 (mouse double minute 2; an essential negative regulator of p53), might radiosensitise LSCC cells.
  • METHODS: We performed clonogenic assays to measure radiosensitivity in a panel of LSCC cell lines (for which we determined p53 mutational status) in the presence and absence of Nutlin-3.
  • RESULTS: LSCC cells harbouring wild-type p53 were significantly radiosensitised by Nutlin-3 (P<0.0001; log-rank scale), and displayed increased cell cycle arrest and significantly increased senescence (P<0.001) in the absence of increased apoptosis; thus, our data suggest that senescence may mediate this increased radiosensitivity.
  • CONCLUSION: This is the first study showing Nutlin-3 as an effective radiosensitiser in LSCC cells that retain wild-type p53.
  • The clinical application of Nutlin-3 might improve local recurrence rates or allow treatment de-escalation in these patients.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Cell Aging / drug effects. Genes, p53. Imidazoles / analysis. Imidazoles / pharmacology. Laryngeal Neoplasms / drug therapy. Piperazines / analysis. Piperazines / pharmacology. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Radiation Tolerance / drug effects. Radiation-Sensitizing Agents / pharmacology
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Cell Survival / drug effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):303-5 [12726854.001]
  • [Cites] Science. 1996 Nov 8;274(5289):948-53 [8875929.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):824-7 [9041179.001]
  • [Cites] Cytometry. 1998 Jan 1;31(1):1-9 [9450519.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2154-61 [10070281.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2455-63 [10499619.001]
  • [Cites] Cell Cycle. 2004 Jul;3(7):900-4 [15254433.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):545-53 [15632057.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1918-24 [15753391.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Surgeon. 2005 Jun;3(3):197-205 [16076005.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3150-9 [16014563.001]
  • [Cites] Cell Cycle. 2006 Jan;5(1):39-42 [16322696.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):411-7 [16505116.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):183-92 [16697662.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):909-23 [17128209.001]
  • [Cites] J Cell Sci. 2006 Dec 15;119(Pt 24):5015-20 [17158908.001]
  • [Cites] Cell Cycle. 2007 Mar 1;6(5):595-605 [17351335.001]
  • [Cites] Methods Mol Biol. 2007;371:21-31 [17634571.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7350-7 [17671205.001]
  • [Cites] Anticancer Drugs. 2007 Oct;18(9):1053-68 [17704656.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):355-66 [17936560.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9862-8 [17942917.001]
  • [Cites] N Engl J Med. 2007 Dec 20;357(25):2552-61 [18094376.001]
  • [Cites] PLoS One. 2008;3(9):e3230 [18800172.001]
  • [Cites] J Dent Res. 2009 Apr;88(4):300-6 [19407148.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14):993-1000 [14707282.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14):1017-26 [14707285.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42 [15234026.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):419-21 [15004525.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):793-805 [15510160.001]
  • [Cites] Arch Otolaryngol. 1981 Nov;107(11):703-10 [7295166.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Oct;91(5):482-91 [6417595.001]
  • [Cites] Br J Radiol. 1985 Jun;58(690):515-28 [4063711.001]
  • [Cites] Genes Dev. 1993 Jul;7(7A):1126-32 [8319905.001]
  • [Cites] Radiat Environ Biophys. 1995 Jun;34(2):79-83 [7652155.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):574-87 [20142252.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):385-94 [10637254.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1813-23 [11747320.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):117-29 [12563311.001]
  • [Cites] Otolaryngol Clin North Am. 2002 Oct;35(5):993-1012 [12587244.001]
  • [Cites] Cell Death Differ. 2003 Apr;10(4):431-42 [12719720.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5187-90 [7585571.001]
  • (PMID = 20588277.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 8313
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Piperazines; 0 / Radiation-Sensitizing Agents; 53IA0V845C / nutlin 3; EC 2.3.2.27 / MDM2 protein, human; EC 2.3.2.27 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC2906734
  •  go-up   go-down


2. Umeda M, Komatsubara H, Ojima Y, Minamikawa T, Shigeta T, Shibuya Y, Yokoo S, Komori T: Lack of survival advantage in patients with advanced, resectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU). Kobe J Med Sci; 2004;50(5-6):189-96
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of survival advantage in patients with advanced, resectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU).
  • Cisplatin-based neoadjuvant chemotherapy (NAC) has been reported to increase survival of patients with nasopharyngeal carcinoma, and organ preservation in those with laryngeal carcinoma, but its efficacy for other head and neck carcinomas is still controversial.
  • We examined the effects of NAC for patients with stage III-IV squamous cell carcinoma of the oral cavity.
  • Although any valid conclusions could not be drawn because of the small number of patients examined here, NAC with CDDP, TXT and 5FU offered no advantages over standard treatment for advanced oral cancer in terms of survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Survival Rate. Taxoids / administration & dosage


3. Lu L, Qiu J, Liu S, Luo W: Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Mol Cancer Ther; 2008 May;7(5):1268-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57.
  • The objective of this study is to evaluate the role of the cyclin-dependent kinase inhibitor p57 in EB1089-inhibited proliferation of human laryngeal squamous carcinoma cells (HEp-2).
  • For interference using silencing RNA (siRNA), HEp-2 cells were transfected with siRNA specific for p57 (siRNA-p57) or a negative control sequence (siRNA-con) followed by treatment with 10 nmol/L EB1089.
  • The effects of EB1089 on cell proliferation were evaluated by 5-bromo-2'-deoxyuridine incorporation and '3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide assay.
  • Cell death and cell cycle dynamics were monitored using flow cytometry.
  • EB1089 significantly inhibited HEp-2 cell proliferation and increased p57 mRNA and protein levels; this was blocked by siRNA-p57 but not by siRNA-con.
  • The EB1089-induced suppression of HEp-2 cell proliferation recovered to near-normal levels with siRNA-p57 transfection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Calcitriol / analogs & derivatives. Carcinoma, Squamous Cell / drug therapy. Cyclin-Dependent Kinase Inhibitor p57 / antagonists & inhibitors. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Humans. Mice. Mice, Nude. RNA, Small Interfering / metabolism. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483314.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / RNA, Small Interfering; FXC9231JVH / Calcitriol; Q0OZ0D9223 / seocalcitol
  •  go-up   go-down


Advertisement
4. Ambriović-Ristov A, Gabrilovac J, Cimbora-Zovko T, Osmak M: Increased adenoviral transduction efficacy in human laryngeal carcinoma cells resistant to cisplatin is associated with increased expression of integrin alphavbeta3 and coxsackie adenovirus receptor. Int J Cancer; 2004 Jul 10;110(5):660-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased adenoviral transduction efficacy in human laryngeal carcinoma cells resistant to cisplatin is associated with increased expression of integrin alphavbeta3 and coxsackie adenovirus receptor.
  • In our study, we investigated molecular mechanisms of increased adenoviral transduction efficacy in cisplatin-resistant human laryngeal carcinoma cells CA3ST as compared to parental cells HEp2.
  • Moderately increased expression of CAR was determined in cisplatin-resistant CA3ST cells using flow cytometry and measurement of wild-type adenovirus Ad5CMVbetagal attachment.
  • The implication of CAR in increased adenoviral transduction efficacy in cisplatin resistant CA3ST cells was further assessed by transduction experiments using adenoviral mutant Ad5FbDelta639 whose entry is only to a very small extent dependent on the presence of CAR.
  • Indeed, Ad5FbDelta639 infected 2.5-fold more, in comparison to wild-type adenovirus, which infected 5-fold more efficiently resistant CA3ST cells than parental HEp2 cells, indicating that increased expression of CAR contributes to increased efficacy of adenoviral transduction.
  • These findings may have significant implications in human gene therapy using adenoviruses, especially in patients after unsuccessful cisplatin treatment.
  • [MeSH-major] Adenoviridae / genetics. Antineoplastic Agents / pharmacology. Carcinoma / metabolism. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Integrin alphaVbeta3 / metabolism. Laryngeal Neoplasms / metabolism. Receptors, Virus / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Membrane / metabolism. Coxsackie and Adenovirus Receptor-Like Membrane Protein. DNA Primers / chemistry. Down-Regulation. Flow Cytometry. Gene Transfer Techniques. Genetic Vectors. Humans. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Up-Regulation. beta-Galactosidase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15146554.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CLMP protein, human; 0 / Coxsackie and Adenovirus Receptor-Like Membrane Protein; 0 / DNA Primers; 0 / Integrin alphaVbeta3; 0 / Receptors, Virus; EC 3.2.1.23 / beta-Galactosidase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Hatoum GF, Patton B, Takita C, Abdel-Wahab M, LaFave K, Weed D, Reis IM: Small cell carcinoma of the head and neck: the university of Miami experience. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):477-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the head and neck: the university of Miami experience.
  • PURPOSE: To describe the University of Miami experience in the treatment of small cell carcinoma of the head and neck.
  • METHODS AND MATERIALS: A total of 12 patients with nonmetastatic small cell carcinoma of the head and neck were treated between April 1987 and September 2007.
  • Radiotherapy was the primary local treatment modality for 8 patients.
  • The Kaplan-Meier estimate of the proportion of small cell head-and-neck cancer patients surviving to 1 and 2 years was 63% and 26%, respectively.
  • The median survival time was 30 months in the tonsil/parotid group compared with 15.2 months in the other group (patients with small cell carcinoma of the sinonasal cavity, nasopharynx, and larynx).
  • A total of 4 patients developed recurrence, 3 of whom had a distant failure component.
  • The treatment modality was not associated with a difference in disease-specific survival.
  • The 1-year disease-specific survival rate was 73% in the radiotherapy or radiotherapy/chemotherapy group compared with 67% in the other group.
  • CONCLUSION: Radiotherapy with or without chemotherapy is a reasonable alternative to surgery for patients with small cell carcinoma of the head and neck.
  • Patients with tonsillar or parotid small cell carcinomas did better than other sites.
  • More aggressive treatment might be warranted for patients with sinonasal carcinoma.
  • The outcome, however, continues to be suboptimal, and more effective therapy is needed because most patients had a component of local and distant failure.
  • [MeSH-major] Carcinoma, Small Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / methods. Disease-Free Survival. Female. Florida. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / radiotherapy. Male. Middle Aged. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / radiotherapy. Nose Neoplasms / drug therapy. Nose Neoplasms / mortality. Nose Neoplasms / radiotherapy. Parotid Neoplasms / drug therapy. Parotid Neoplasms / mortality. Parotid Neoplasms / radiotherapy. Retrospective Studies. Tonsillar Neoplasms / drug therapy. Tonsillar Neoplasms / mortality. Tonsillar Neoplasms / radiotherapy. Universities

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004574.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Sone M, Uchida I, Tominaga M, Sugiura S, Nagasaka T, Nakashima T: Small cell carcinoma of the larynx treated with irinotecan and cisplatin. Auris Nasus Larynx; 2006 Jun;33(2):223-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the larynx treated with irinotecan and cisplatin.
  • We report a case of advanced small cell carcinoma in the larynx, which was treated with Irinotecan hydrochloride (CPT-11) chemotherapy.
  • The patient was free of disease for 4 years after treatment.
  • Several chemotherapeutic agents for small cell carcinoma have been proposed; however, median survival time has been miserable, especially in advanced cases.
  • For the cure of the aggressive lethal behavior of this disease, chemotherapy with CPT-11 might be effective to improve median survival of patients with small cell carcinomas of the larynx.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Cisplatin / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376504.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Yuan ZY, Guan ZZ, Zhou ZM, Xia Y, Huang WZ, Yang XL: [Extrapulmonary small cell carcinoma in 52 patients]. Ai Zheng; 2006 Sep;25(9):1131-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapulmonary small cell carcinoma in 52 patients].
  • BACKGROUND & OBJECTIVE: The majority of small cell carcinoma occurs in the lung.
  • Extrapulmonary small cell carcinoma (ESCC) has been recognized as a clinicopathologic entity distinct from small cell carcinoma of the lung.
  • The study was to investigate the clinical characteristics, therapy, and prognosis of ESCC.
  • Of the 53 cases of ESCC, 33 (62.3%) were detected in the esophagus, 5 in the cervix, 4 in the larynx, 3 in the pharynx, 2 in the upper sinus, 2 in the rectum and sublingual gland, 1 in the thyroid gland, 1 in the pleura, and 1 in the liver.
  • Patients with ED mostly received platinum-based chemotherapy, for which the response rate was 69.2%.
  • Patients with LD were treated with a variety of therapeutic modalities: 7 were treated with surgery plus radiochemotherapy, 3 with surgery plus radiotherapy, 18 with surgery plus chemotherapy, 6 with radiotherapy plus chemotherapy, 4 with radiotherapy alone, and 2 with chemotherapy alone.
  • The median survival time (MST) was 20 months for all patients, and the 1-and 3-year survival rates were 41.3% and 31.4%.
  • Multimodality therapy has become increasingly used for the majority of patients with LD-ESCC.
  • Combination chemotherapy has been a major treatment for patients with ED-ESCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell. Esophageal Neoplasms. Radiotherapy, High-Energy
  • [MeSH-minor] Adult. Aged. Cobalt Radioisotopes. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Male. Middle Aged. Particle Accelerators. Retrospective Studies. Survival Rate. Treatment Outcome. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965656.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


8. Fic M, Podhorska-Okolow M, Dziegiel P, Gebarowska E, Wysocka T, Drag-Zalesinska M, Zabel M: Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2). In Vivo; 2007 May-Jun;21(3):513-8
Hazardous Substances Data Bank. MELATONIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2).
  • However, few data are available on the effects of MLT on cytotoxicity of antineoplastic drugs toward tumor cells in vitro.
  • The present study aimed at the evaluation of effects of MLT and of DOX on selected cell lines.
  • The experiments were conducted on human keratinocytes (primary culture), non-small cell lung cancer (A-549) and laryngeal cancer cell lines (HEp-2).
  • In keratinocytes and in A-549 cells, MLT used at pharmacological concentrations (0.1 and 1.0 mM) was observed to intensify apoptotic lesions.
  • MLT exerted no clear-cut effects on the HEp-2 cell line.
  • In contrast, DOX at concentrations of 0.1 and 1.0 microg/ml intensified apoptosis and augmented the frequency of necrotic lesions in cell nuclei in all the examined cell lines.
  • MLT intensified cytotoxicity of DOX in all cell lines, significantly decreasing cell numbers and promoting apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antioxidants / pharmacology. Doxorubicin / pharmacology. Keratinocytes / drug effects. Melatonin / pharmacology. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Cell Line, Tumor. Cell Survival / drug effects. Comet Assay. DNA Damage. Dose-Response Relationship, Drug. Drug Combinations. Drug Screening Assays, Antitumor. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Necrosis

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591362.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Drug Combinations; 80168379AG / Doxorubicin; JL5DK93RCL / Melatonin
  •  go-up   go-down


9. Lecanu JB, Monceaux G, Périé S, Angelard B, St Guily JL: Conservative surgery in T3-T4 pharyngolaryngeal squamous cell carcinoma: an alternative to radiation therapy and to total laryngectomy for good responders to induction chemotherapy. Laryngoscope; 2000 Mar;110(3 Pt 1):412-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative surgery in T3-T4 pharyngolaryngeal squamous cell carcinoma: an alternative to radiation therapy and to total laryngectomy for good responders to induction chemotherapy.
  • OBJECTIVE: To evaluate the possibility of preservation of the larynx after neoadjuvant chemotherapy by performing a conservative surgery instead of total laryngectomy initially planned, in patients with previously untreated laryngeal and piriform sinus squamous cell carcinoma (SCC).
  • METHODS: A total of 115 patients treated at Tenon Hospital with induction chemotherapy from 1985 to 1995, all with initial indication of radical surgery, were available for the study.
  • The clinical tumor response was evaluated after three cycles of chemotherapy.
  • According to this response, to preserve laryngeal functions, some patients had a modification of the treatment initially planned: radiation therapy essentially for complete responders, and conservative surgery for some partial responders.
  • RESULTS: Of 69 patients with laryngeal cancer, 14 were treated by partial laryngectomy and 19 by radiation therapy; of 46 patients with piriform sinus cancer, 8 were treated by partial surgery and 12 by radiation therapy; the other patients were treated as was initially planned (total laryngectomy with partial pharyngectomy).
  • Overall survival rates, estimated by the Kaplan-Meier method, were not statistically different between the three treatment groups.
  • The laryngeal functions were preserved in 54% of the patients who were alive at 3 years.
  • CONCLUSION: This report is a retrospective study, but these results suggest the possibility of using conservative surgery, instead of initially planned total laryngectomy, for good responders to induction chemotherapy with a small residual tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery. Laryngectomy. Neoadjuvant Therapy. Pharyngeal Neoplasms / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10718429.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Pignon JP, Bourhis J, Domenge C, Designé L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet; 2000 Mar 18;355(9208):949-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.
  • BACKGROUND: Despite more than 70 randomised trials, the effect of chemotherapy on non-metastatic head and neck squamous-cell carcinoma remains uncertain.
  • We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment.
  • We included patients with carcinoma of the oropharynx, oral cavity, larynx, or hypopharynx.
  • FINDINGS: The main meta-analysis of 63 trials (10,741 patients) of locoregional treatment with or without chemotherapy yielded a pooled hazard ratio of death of 0.90 (95% CI 0.85-0.94, p<0.0001), corresponding to an absolute survival benefit of 4% at 2 and 5 years in favour of chemotherapy.
  • There was no significant benefit associated with adjuvant or neoadjuvant chemotherapy.
  • Chemotherapy given concomitantly to radiotherapy gave significant benefits, but heterogeneity of the results prohibits firm conclusions.
  • Meta-analysis of six trials (861 patients) comparing neoadjuvant chemotherapy plus radiotherapy with concomitant or alternating radiochemotherapy yielded a hazard ratio of 0.91 (0.79-1.06) in favour of concomitant or alternating radiochemotherapy.
  • Three larynx-preservation trials (602 patients) compared radical surgery plus radiotherapy with neoadjuvant chemotherapy plus radiotherapy in responders or radical surgery and radiotherapy in non-responders.
  • The hazard ratio of death in the chemotherapy arm as compared with the control arm was 1.19 (0.97-1.46).
  • INTERPRETATION: Because the main meta-analysis showed only a small significant survival benefit in favour of chemotherapy, the routine use of chemotherapy is debatable.
  • For larynx preservation, the non-significant negative effect of chemotherapy in the organ-preservation strategy indicates that this procedure must remain investigational.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / therapy. Proportional Hazards Models. Randomized Controlled Trials as Topic. Treatment Outcome


11. George A, Uppal H, Phelan C, Hughes R: Extra-pulmonary small cell carcinoma of the neopharynx: case report and review of neopharyngeal tumours after total laryngectomy. J Laryngol Otol; 2010 Feb;124(2):216-9
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-pulmonary small cell carcinoma of the neopharynx: case report and review of neopharyngeal tumours after total laryngectomy.
  • OBJECTIVE: We report the first documented case in the world literature of primary extra-pulmonary small cell carcinoma occurring in the neopharynx following laryngectomy.
  • METHOD: We present a case report and a review of the world literature regarding the management of tumours of the neopharynx and extra-pulmonary small cell carcinoma.
  • RESULTS: The paucity of cases of extra-pulmonary small cell carcinoma has resulted in many departments managing this neoplasm similarly to pulmonary small cell cancer.
  • However, the site of the primary can have an impact on disease survival and treatment options.
  • CONCLUSION: Neopharyngeal small cell carcinoma has not previously been reported.
  • It should be managed in the same way as other extra-pulmonary small cell carcinomas occurring within the pharynx or larynx, with combined multi-drug chemotherapy and radiotherapy.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Pharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Agents / therapeutic use. Deglutition Disorders / etiology. Humans. Laryngeal Neoplasms / surgery. Laryngectomy. Male. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640316.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 20
  •  go-up   go-down


12. Herchenhorn D, Dias FL, Ferreira CG, Araújo CM, Lima RA, Small IA, Kligerman J: Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation. ORL J Otorhinolaryngol Relat Spec; 2008;70(6):381-8
MedlinePlus Health Information. consumer health - Choking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation.
  • HYPOTHESIS: The combination of chemotherapy and radiotherapy is a standard nonsurgical treatment for locally advanced laryngeal cancer.
  • Nevertheless, there are no validated markers to predict the outcome of nonsurgical therapies.
  • Prognostic factors such as stage, age, performance status, number of chemotherapy cycles, radiotherapy dose, stage VIb disease, and previous tracheotomy were analyzed using the Cox's proportional hazard model.
  • PATIENTS AND METHODS: Patients with stage III/IV laryngeal carcinoma were prospectively selected.
  • Treatment consisted of cisplatin 100 mg/m(2) every 3 weeks for 3 cycles, radiotherapy to a total dose of 70.2 Gy and salvage surgery.
  • RESULTS: Forty-nine patients were analyzed; tracheotomy was performed in 12 patients (24.5%) before therapy.
  • CONCLUSIONS: Previous tracheotomy is a negative prognostic factor for patients submitted to chemotherapy combined with radiotherapy and should be considered as a negative clinical prognostic factor in the selection of patients for more aggressive treatment strategies.
  • [MeSH-major] Airway Obstruction / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / therapy. Tracheotomy / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Predictive Value of Tests. Probability. Prognosis. Proportional Hazards Models. Prospective Studies. Radiotherapy, Adjuvant. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18984974.001).
  • [ISSN] 1423-0275
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Blumenschein G, Lu C, Kies M, Glisson B, Papadimitrakopoulou V, Zinner R, Kim E, Gillenwater A, Chiao J, Hong W: Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer(SCCHN). J Clin Oncol; 2004 Jul 15;22(14_suppl):5578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preclinical studies demonstrated that SAHA has growth inhibitory and apoptosis-inducing activity in SCCHN cell lines in vitro.
  • In a phase I trial of oral SAHA administered once a day or twice a day, a partial response was observed in a pt with metastatic laryngeal carcinoma.
  • METHODS: Eligible pts must have recurrent and/or metastatic SCCHN unresponsive to or intolerant of conventional chemotherapy (up to two prior chemotherapies including neoadjuvant, adjuvant, and concomitant chemotherapy/radiation); ECOG performance status 0-2; adequate hematologic, hepatic, and renal function; able to swallow capsules; have measurable disease; = 4 weeks from prior chemotherapy, radiation therapy, major surgery or investigational anticancer therapy and have recovered from prior toxicities.
  • 1 pt withdrew consent prior to starting therapy.
  • Prior therapies included radiation in 9 pts and chemotherapy in all 12 pts; 11 patients received platinum, 8 patients received both taxanes and platinum.
  • Toxicity has been acceptable with 1 pt discontinuing therapy for grade 3 anorexia.
  • Other grade 3-4 drug-related toxicities included anemia (n=1), anorexia (n=1), back pain (n=1), fatigue (n=1), and thrombocytopenia (n=3).
  • CONCLUSIONS: SAHA at 400 mg qd appears to be well tolerated and has modest single agent activity in this small group of heavily pre-treated pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Renner G: Small cell carcinoma of the head and neck: a review. Semin Oncol; 2007 Feb;34(1):3-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the head and neck: a review.
  • Small cell carcinoma (SCC) has become recognized as a distinct, though relatively infrequent, clinical pathology that occurs in multiple sites throughout the head and neck.
  • Among the head and neck sites, the frequency of SCC is greatest in the larynx, with salivary glands and the sinonasal region comprising the other principle areas of origin.
  • Controversy exist as to whether SCC can develop as a distinct entity in the thyroid, with most tumors that previously would have been considered as SCC now found to be lymphomas or variant forms of other types of thyroid malignancy.
  • Treatment may include surgical resection, radiotherapy, chemotherapy, or some combination of these modalities.
  • For this reason, recommendations for treatment of SCC arising in the head and neck are based primarily on retrospective data from various small case series and on comparative data for treatment of SCC of bronchogenic and other extrapulmonary origin.
  • Although patients with truly limited local disease may enjoy some prolonged survival, most patients with this tumor do poorly despite all current attempts at treatment.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Cranial Irradiation. Female. Humans. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Male. Nose Neoplasms / epidemiology. Nose Neoplasms / pathology. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / epidemiology. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy. Prognosis. Salivary Gland Neoplasms / epidemiology. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / therapy. Thyroid Neoplasms / epidemiology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270660.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 144
  •  go-up   go-down


15. Gao X, Fisher SG, Mohideen N, Emami B: Second primary cancers in patients with laryngeal cancer: a population-based study. Int J Radiat Oncol Biol Phys; 2003 Jun 1;56(2):427-35
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary cancers in patients with laryngeal cancer: a population-based study.
  • BACKGROUND: Literature regarding incidence of site-specific second cancers after laryngeal cancer is limited.
  • METHODS: Second primaries after laryngeal cancer in the SEER database (1973-1996) were analyzed for incidence, relative risk compared with the general population, and potential risk factors, including radiotherapy.
  • Information on chemotherapy and tobacco smoking was not available in the SEER database.
  • RESULTS: Of 20,074 laryngeal cancer patients surviving at least 3 months, 3533 (17.6%) developed second cancers.
  • Compared with age-adjusted, gender, and tumor-specific rates in the general population, laryngeal cancer patients had higher risks of second cancers overall (observed-to-expected ratio [O/E] = 1.68, 95% confidence interval [CI] = 1.58-1.79), head-and-neck (4.81 [4.31-5.58]), esophageal (3.99 [3.29-4.83]), and lung (3.56 [3.34-3.79]) cancer.
  • Advanced age at initial diagnosis was associated with increased risks of second cancers (p = 0.0001).
  • CONCLUSIONS: Second cancers after laryngeal cancer are common, especially for long-term survivors.
  • Radiotherapy was associated with a small increased risk of developing second cancers overall and long-term risk of head-and-neck cancers.
  • This data should be interpreted with caution in light of the lack of information on chemotherapy and tobacco smoking in the SEER database.
  • Prevention and early detection are indicated.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Laryngeal Neoplasms / epidemiology. Neoplasms, Second Primary / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12738317.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Janot F, Julieron M: [Functional surgery for head and neck squamous cell carcinoma]. Bull Cancer; 2002 Dec;89(12):1011-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Functional surgery for head and neck squamous cell carcinoma].
  • [Transliterated title] Chirurgie conservatrice des cancers des voies aérodigestives supérieures.
  • Surgery for head and neck squamous cell carcinoma can alter speech, swallowing, and cosmoses.
  • Recent tendency is to avoid mutilating surgery unless the tumour is aggressive or resistant to chemotherapy and or radiotherapy.
  • Functional surgery is being widely employed, and for example it may vary between conventional partial surgery and endoscopic laser surgery for small sized vocal cord cancers.
  • Various new reconstructive procedures have been developed to help early functional restoration.
  • Few recently developed techniques can be also employed in selected cases of laryngo-pharyngeal cancers to avoid permanent laryngeal mutilation.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Glossectomy. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Laryngectomy. Laryngoscopy. Mandible / surgery. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / radiotherapy. Pharyngeal Neoplasms / surgery. Pharyngectomy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12525359.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


17. Capelli M, Bertino G, Morbini P, Villa C, Zorzi S, Benazzo M: Neuroendocrine carcinomas of the upper airways: a small case series with histopathological considerations. Tumori; 2007 Sep-Oct;93(5):499-503
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine carcinomas of the upper airways: a small case series with histopathological considerations.
  • In the head and neck region they are most common in the larynx, where they represent 0.5-1% of epithelial cancers.
  • Diagnosis requires the recognition of the typical neuroendocrine architecture and morphology and the immunohistochemical confirmation of neuroendocrine differentiation.
  • In the 1991 WHO classification laryngeal neuroendocrine carcinomas have been divided into carcinoids, atypical carcinoids, small cell carcinomas and paragangliomas.
  • We present the clinical and histopathological features of 2 moderately differentiated neuroendocrine carcinomas of the larynx, one large cell poorly differentiated neuroendocrine carcinoma of the oropharynx, and one small cell carcinoma of the minor salivary glands of the tongue.
  • The patient with small cell carcinoma was free from disease 26 months after radical surgery, while the other patients showed liver, lung and bone metastases 18, 26 and 24 months after the diagnosis despite radical surgery or concomitant intra-arterial chemotherapy and radiotherapy.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Lung Neoplasms / pathology. Neuroendocrine Tumors / pathology. Oropharyngeal Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Combined Modality Therapy. Humans. Immunoenzyme Techniques. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038886.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Herchenhorn D, Dias FL, Viegas CM, Federico MH, Araújo CM, Small I, Bezerra M, Fontão K, Knust RE, Ferreira CG, Martins RG: Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):696-702
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
  • PURPOSE: Erlotinib, an oral tyrosine kinase inhibitor, is active against head-and-neck squamous cell carcinoma (HNSCC) and possibly has a synergistic interaction with chemotherapy and radiotherapy.
  • METHODS AND MATERIALS: In this Phase I/II trial 100 mg/m(2) of cisplatin was administered on Days 8, 29, and 50, and radiotherapy at 70 Gy was started on Day 8.
  • Of the 31 patients receiving a 150-mg daily dose of erlotinib, 23 (74%; 95% confidence interval, 56.8%-86.3%) had a complete response, 3 were disease free after salvage surgery, 4 had inoperable residual disease, and 1 died of sepsis during treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Brazil. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Confidence Intervals. Drug Administration Schedule. Drug Eruptions / etiology. Erlotinib Hydrochloride. Female. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / radiotherapy. Male. Middle Aged. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radiotherapy. Quinazolines / administration & dosage. Quinazolines / adverse effects. Radiotherapy Dosage. Salvage Therapy / methods. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20421154.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Issing WJ, Taleban B, Tauber S: Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol; 2003 Sep;260(8):436-43
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of carcinoma of unknown primary in the head and neck.
  • Carcinoma of unknown primary is defined as the histological diagnosis of metastasis without the detection of a primary tumor.
  • The most frequent histopathological results of CUP metastases are adenocarcinoma, followed by undifferentiated carcinoma and squamous cell carcinoma.
  • Squamous cell carcinoma (n=123) was the predominant histopathological finding of the cervical lymph nodes.
  • Primary radiotherapy was the treatment of choice in 28 patients; eight patients received combined radio-chemotherapy as the primary treatment and seven patients were treated with chemotherapy alone.
  • Six patients had no treatment.
  • Comparison of different treatment protocols revealed a significant difference in patient survival: in comparison with primary radiotherapy alone or neck dissection and postoperative radiotherapy, the survival rate improved significantly in patients that received a bilateral tonsillectomy in addition to neck dissection and postoperative radiotherapy.
  • The treatment of choice in patients with cervical CUP should be a surgical procedure including (radical) neck dissection and diagnostic bilateral tonsillectomy followed by postoperative radiation of the cervical lymph drainage.
  • Additional postoperative radiation of the entire pharyngeal and laryngeal mucosa should also be considered in order to treat a possible small primary tumor in this region.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / therapy. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / therapy. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / therapy

  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1966 Oct;112(4):547-53 [5915300.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Jul;259(6):325-33 [12115082.001]
  • [Cites] Ann Surg. 1950 Nov;132(5):867-87 [14771797.001]
  • [Cites] Arch Intern Med. 1988 Sep;148(9):2035-9 [3046543.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1980 Apr;59(4):221-6 [7442406.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(4):222-8 [7546677.001]
  • [Cites] Strahlentherapie. 1972 Sep;144(3):267-75 [5085135.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):727-33 [11395241.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Dec;116(12):1388-93 [2248737.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Sep;123(3):294-301 [10964310.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1980 Oct-Nov;97(10-11):805-11 [7212532.001]
  • [Cites] Surg Gynecol Obstet. 1957 May;104(5):607-17 [13433258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):291-6 [9308930.001]
  • [Cites] Acta Radiol Oncol. 1983;22(1):17-22 [6305128.001]
  • [Cites] Clin Radiol. 1980 May;31(3):355-8 [7428277.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):273-8 [8503023.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):743-9 [1618667.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):33-40 [9886695.001]
  • [Cites] Head Neck. 1990 May-Jun;12(3):204-9 [2358330.001]
  • [Cites] Arch Otolaryngol. 1972 Mar;95(3):240-4 [5013268.001]
  • [Cites] Am J Surg. 1983 Oct;146(4):441-6 [6625088.001]
  • [Cites] Cancer. 1973 Apr;31(4):854-9 [4706050.001]
  • [Cites] Otolaryngol Clin North Am. 1980;13(3):489-98 [7003479.001]
  • [Cites] Strahlenther Onkol. 1988 Mar;164(3):129-35 [3353851.001]
  • [Cites] HNO. 1995 May;43(5):299-303 [7607915.001]
  • [Cites] J Laryngol Otol. 1970 Mar;84(3):249-65 [5441914.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):121-9 [10799723.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Acta Otolaryngol. 2002 Jul;122(5):569-74 [12206272.001]
  • (PMID = 12684829.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Zips D, Le K, Yaromina A, Dörfler A, Eicheler W, Zhou X, Geyer P, Hilberg F, Baumann M: Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. Radiother Oncol; 2009 Sep;92(3):405-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas.
  • BACKGROUND AND PURPOSE: To test the effect of BIBF 1120, a novel small molecule inhibitor of multiple angiogenic receptor tyrosine kinases, on the hypoxia and radiation response of tumours.
  • MATERIALS AND METHODS: Poorly differentiated human squamous cell carcinoma FaDu growing in nude mice was treated with BIBF 1120 and investigated by functional histology.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Indoles / pharmacology. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Neovascularization, Pathologic / prevention & control
  • [MeSH-minor] Animals. Cell Hypoxia / drug effects. Cell Hypoxia / radiation effects. Cell Survival / drug effects. Cell Survival / radiation effects. Disease Models, Animal. Dose Fractionation. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Immunohistochemistry. Male. Mice. Mice, Nude. Neoplasm Transplantation. Probability. Radiation Tolerance / drug effects. Random Allocation. Reference Values

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409639.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Indoles; G6HRD2P839 / nintedanib
  •  go-up   go-down


21. Ferlito A, Silver CE, Bradford CR, Rinaldo A: Neuroendocrine neoplasms of the larynx: an overview. Head Neck; 2009 Dec;31(12):1634-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine neoplasms of the larynx: an overview.
  • Neuroendocrine neoplasms of the larynx are rare but are the most common nonsquamous tumors of this organ.
  • In the past, there has been considerable confusion about the nature and classification of these neoplasms, but the current consensus is that there are 4 different types of laryngeal neuroendocrine tumors composed of paraganglioma, typical carcinoid, atypical carcinoid tumor, and small cell neuroendocrine carcinoma.
  • Carcinoids and small cell neuroendocrine carcinomas are epithelial neoplasms, whereas paragangliomas are of neural origin.
  • Diagnosis is based primarily on light microscopy and confirmed by immunohistochemistry and electron microscopy.
  • Precise diagnosis is essential because the natural history, treatment, and prognosis vary widely for the different neoplastic categories.
  • They are treated by partial or total laryngectomy with elective or therapeutic neck dissection.
  • Small cell neuroendocrine carcinomas are highly aggressive and should be considered disseminated at initial diagnosis.
  • The treatment is by irradiation and chemotherapy as surgery has proven to be of a little benefit.
  • Atypical carcinoid tumors have a 5-year survival rate of approximately 50%, which decreases with time.
  • The prognosis of small cell neuroendocrine carcinoma of the larynx is dismal, with 5-year survival rates of 5%.
  • The biological behavior of laryngeal paraganglioma is generally benign and the prognosis is excellent.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Laryngectomy / methods. Male. Neck Dissection / methods. Neoplasm Staging. Paraganglioma / mortality. Paraganglioma / pathology. Paraganglioma / therapy. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536850.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 89
  •  go-up   go-down


22. Teknos TN, Myers LL, Bradford CR, Chepeha DB: Free tissue reconstruction of the hypopharynx after organ preservation therapy: analysis of wound complications. Laryngoscope; 2001 Jul;111(7):1192-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free tissue reconstruction of the hypopharynx after organ preservation therapy: analysis of wound complications.
  • PURPOSE: Previous series have demonstrated a 77% rate of major wound complications in salvage surgery of the larynx following organ preservation protocols.
  • The purpose of this study is to determine the incidence of wound complications in these patients when microvascular free tissue transfers are used for reconstruction of the hypopharynx.
  • PATIENTS AND METHOD: We reviewed the medical records of 42 patients with stage III and IV laryngeal squamous cell carcinoma treated with an organ-sparing protocol consisting of induction chemotherapy followed by definitive radiation therapy.
  • Ten of these patients who required surgical salvage were reconstructed using radial forearm free tissue or lateral arm transfer and constitute the study group.
  • One patient in this study group had a small pharyngocutaneous fistula that resolved with conservative therapy after 1 week.
  • The average free tissue flap size was 94.3 cm(2) (range, 45-165 cm(2)).
  • Average harvest and ischemia times were 59 minutes (range, 41-87 min) and 187.7 minutes (range, 120-240 min), respectively.
  • CONCLUSIONS: Our results suggest that free tissue transfer reconstruction of the hypopharynx is the preferred method of reconstruction following combined chemotherapy and radiation therapy protocols.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Hypopharynx / surgery. Laryngeal Neoplasms / surgery. Reconstructive Surgical Procedures. Surgical Flaps. Wound Healing
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Laryngectomy. Length of Stay. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568540.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Marioni G, D'Alessandro E, Bertolin A, Staffieri A: Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges. Acta Otolaryngol; 2010;130(1):4-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges.
  • CONCLUSIONS: Survivin expression should be studied as a potential hallmark of higher risk oral, oropharyngeal and laryngeal squamous cell carcinomas (SCCs) to develop loco-regional recurrences.
  • These outcomes could have a significant impact on both the treatment modalities and the intensity of post-treatment follow-up.
  • Further investigation is necessary before considering elective neck dissection in patients with laryngeal SCC with high survivin expression.
  • OBJECTIVES: Functioning simultaneously at cell division and apoptosis inhibition, survivin, a member of the inhibitor of apoptosis proteins family, plays a pivotal role in determining cell survival.
  • This review focuses on the attempts to translate survivin biologic properties toward both a diagnostic/prognostic tool and a novel therapeutic target in head and neck SCC (HNSCC).
  • MATERIALS AND METHODS: An exhaustive review of literature was performed to investigate available evidence about survivin expression, biological role and therapeutic potential in HNSCC.
  • RESULTS: Multiple evidence indicates that, in HNSCC cell lines, survivin inhibition by gene therapy and by small molecule inhibitors significantly increases the anti-tumour activity of several cytotoxic and other targeted therapies.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Gene Expression Regulation, Neoplastic / genetics. Microtubule-Associated Proteins / genetics. Otorhinolaryngologic Neoplasms / genetics
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Cell Line, Tumor. Combined Modality Therapy. Gene Transfer Techniques. Genetic Therapy. Humans. Inhibitor of Apoptosis Proteins. Mice. Mice, Inbred BALB C. Mice, Nude. Neck Dissection. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Oligonucleotides, Antisense / therapeutic use. Protein Isoforms / genetics. RNA, Messenger / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322702.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Oligonucleotides, Antisense; 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


24. Liu DH, Wang XM, Zhang LJ, Dai SW, Liu LY, Liu JF, Wu SS, Yang SY, Fu S, Xiao XY, He DC: Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci; 2007 Feb;20(1):33-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To identify serum diagnosis or progression biomarkers in patients with lung cancer using protein chip profiling analysis.
  • METHOD: Profiling analysis was performed on 450 sera collected from 213 patients with lung cancer, 19 with pneumonia, 16 with pulmonary tuberculosis, 65 with laryngeal carcinoma, 55 with laryngopharyngeal carcinoma patients, and 82 normal individuals.
  • A new strategy was developed to identify the biomarkers on chip by trypsin pre-digestion.
  • The level and percentage of 11.6 kDa protein progressively increased with the clinical stages I-IV and were also higher in patients with squamous cell carcinoma than in other subtypes.
  • This biomarker could be decreased after operation or chemotherapy.
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Small Cell / blood. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Peptides / blood. Protein Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458139.001).
  • [ISSN] 0895-3988
  • [Journal-full-title] Biomedical and environmental sciences : BES
  • [ISO-abbreviation] Biomed. Environ. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptides; 0 / Serum Amyloid A Protein
  •  go-up   go-down


25. Curran WJ: New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology; 2002;63 Suppl 2:29-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The institution of combined modality therapy for unresected solid tumors has resulted in significant improvements in tumor control and survival benefit compared with radiotherapy (RT) alone.
  • A number of chemotherapy agents that can enhance the effectiveness of RT, such as cisplatin and 5-fluorouracil, are now considered standard treatment for patients with a number of cancer types.
  • This article provides an update of some important, recently completed and ongoing clinical trials evaluating novel chemoradiation protocols, with examples taken primarily from studies conducted by the Radiation Therapy Oncology Group (RTOG).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drugs, Investigational / therapeutic use. Neoplasms / drug therapy. Neoplasms / radiotherapy
  • [MeSH-minor] Alkyl and Aryl Transferases / antagonists & inhibitors. Angiogenesis Inhibitors / therapeutic use. Angiostatins. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Chemotherapy, Adjuvant. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cyclooxygenase Inhibitors / therapeutic use. Dose Fractionation. Endothelial Growth Factors / therapeutic use. Enzyme Inhibitors / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Farnesyltranstransferase. Female. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Humans. Indoles / therapeutic use. Intercellular Signaling Peptides and Proteins / therapeutic use. Isoenzymes / antagonists & inhibitors. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Lymphokines / therapeutic use. Male. Membrane Proteins. Peptide Fragments / therapeutic use. Plasminogen / therapeutic use. Prostaglandin-Endoperoxide Synthases. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Pyrroles / therapeutic use. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Treatment Outcome. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12466642.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Drugs, Investigational; 0 / Endothelial Growth Factors; 0 / Enzyme Inhibitors; 0 / Indoles; 0 / Intercellular Signaling Peptides and Proteins; 0 / Isoenzymes; 0 / Lymphokines; 0 / Membrane Proteins; 0 / Peptide Fragments; 0 / Pyrroles; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 71IA9S35AJ / Semaxinib; 86090-08-6 / Angiostatins; 9001-91-6 / Plasminogen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 2.5.- / Alkyl and Aryl Transferases; EC 2.5.1.29 / Farnesyltranstransferase
  • [Number-of-references] 32
  •  go-up   go-down


26. Logemann JA, Rademaker AW, Pauloski BR, Lazarus CL, Mittal BB, Brockstein B, MacCracken E, Haraf DJ, Vokes EE, Newman LA, Liu D: Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck; 2006 Jan;28(1):64-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation.
  • BACKGROUND: The relationship between type of chemoradiation treatment, site of disease, and swallowing function has not been sufficiently examined in patients with head and neck cancer treated primarily with chemoradiation.
  • METHODS: Fifty-three patients with advanced-stage head and neck cancer were evaluated before and 3 months after chemoradiation treatment to define their swallowing disorders and characterize their swallowing physiology by site of lesion and chemoradiation protocol.
  • RESULTS: The most common disorders at baseline and 3 months after treatment were reduced tongue base retraction, reduced tongue strength, and slowed or delayed laryngeal vestibule closure.
  • Frequency of functional swallow did not differ significantly across disease sites after treatment, although frequency of disorders was different at various sites of lesion.
  • The effects of the chemotherapy protocols were small.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Deglutition Disorders / etiology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Deglutition / drug effects. Deglutition / physiology. Deglutition / radiation effects. Female. Humans. Male. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc. Head Neck 27: XXX-XXX, 2005.
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Head Neck. 2002 Jan;24(1):68-77 [11774405.001]
  • [Cites] Head Neck. 2002 Jun;24(6):555-65 [12112553.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):320-6 [12525525.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1689-97 [12738722.001]
  • [Cites] Head Neck. 2003 Jun;25(6):432-7 [12784234.001]
  • [Cites] Gastrointest Radiol. 1983;8(2):97-104 [6343174.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 May;14(5):839-48 [3360653.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):711-6 [3138220.001]
  • [Cites] Biometrics. 1988 Dec;44(4):1049-60 [3233245.001]
  • [Cites] Rev Stomatol Chir Maxillofac. 1989;90(5):334-6 [2799248.001]
  • [Cites] Dysphagia. 1991;6(2):120-2 [1935259.001]
  • [Cites] J Speech Hear Res. 1994 Apr;37(2):314-25 [8028312.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):419-22 [7977964.001]
  • [Cites] Laryngoscope. 1996 Sep;106(9 Pt 1):1157-66 [8822723.001]
  • [Cites] Head Neck. 1999 Oct;21(7):595-601 [10487945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):577-87 [10524409.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2000 Mar;109(3):320-5 [10737318.001]
  • [Cites] Head Neck. 2000 Aug;22(5):474-82 [10897107.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1961-9 [11283128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] Int J Cancer. 2001;96 Suppl:61-70 [11992387.001]
  • (PMID = 16302193.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA040007; United States / NIDCR NIH HHS / DE / P50 DE011921
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS7896; NLM/ PMC1380204
  •  go-up   go-down


27. Sarkar S, Kundu AK, Chakrabarti S: Lungs: victim of synchronous double malignancies. J Assoc Physicians India; 2007 Mar;55:235-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CT-guided FNAC from the mass lesion was consistent with the diagnosis of non-small cell lung carcinoma (NSCLC).
  • Both FNAC and excisional biopsy of the testicular mass confirmed the diagnosis of immature teratoma with choriocarcinoma, a form of non-seminomatous germ cell tumour (NSGCT).
  • With chemotherapy all metastatic lesions of lung and SVC syndrome disappeared, and the tumour-marker levels decreased.
  • However, the opacity in RUZ progessed to involve right recurrent laryngeal nerve at thoracic inlet, metastasized to the brain, and the patient expired after 4th cycle of chemotherapy.
  • [MeSH-major] Choriocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Teratoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598338.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


28. Annino DJ Jr, Goguen LA: Mitomycin C for the treatment of pharyngoesophageal stricture after total laryngopharyngectomy and microvascular free tissue reconstruction. Laryngoscope; 2003 Sep;113(9):1499-502
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitomycin C for the treatment of pharyngoesophageal stricture after total laryngopharyngectomy and microvascular free tissue reconstruction.
  • STUDY DESIGN: Five patients since 1998 underwent evaluation and treatment for pharyngoesophageal stricture after total laryngopharyngectomy and free flap reconstruction.
  • All patients underwent barium swallow, computed tomography, and endoscopic examination and were proven to be free of recurrent disease.
  • All patients were happy with the treatment results.
  • CONCLUSIONS: This small case series suggests that MMC is a safe and effective adjunctive treatment for pharyngoesophageal stricture after total laryngopharyngectomy and free flap reconstruction.
  • [MeSH-major] Esophageal Stenosis / drug therapy. Laryngectomy. Microsurgery. Mitomycin / administration & dosage. Nucleic Acid Synthesis Inhibitors / administration & dosage. Pharyngeal Diseases / drug therapy. Pharyngectomy. Postoperative Complications / drug therapy. Surgical Flaps / blood supply
  • [MeSH-minor] Adenocarcinoma / surgery. Administration, Topical. Aged. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Constriction, Pathologic / diagnosis. Constriction, Pathologic / drug therapy. Deglutition Disorders / diagnosis. Deglutition Disorders / drug therapy. Dilatation. Esophageal Neoplasms / surgery. Esophagoscopy. Female. Humans. Laryngeal Neoplasms / surgery. Male. Pharyngeal Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Throat Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12972923.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nucleic Acid Synthesis Inhibitors; 50SG953SK6 / Mitomycin
  •  go-up   go-down


29. Durdux C: [Cisplatin and derivatives with radiation therapy: for what clinical use?]. Cancer Radiother; 2004 Nov;8 Suppl 1:S88-94
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cisplatin and derivatives with radiation therapy: for what clinical use?].
  • The first part of this overview will describe biological mechanisms of interaction between radiation therapy and platinum derivatives.
  • [MeSH-major] Carboplatin / therapeutic use. Cisplatin / therapeutic use. Neoplasms / drug therapy. Neoplasms / radiotherapy. Organoplatinum Compounds / therapeutic use. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Animals. Anus Neoplasms / drug therapy. Anus Neoplasms / mortality. Anus Neoplasms / radiotherapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / radiotherapy. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Female. Humans. Hydroxyurea / administration & dosage. Hydroxyurea / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Leukemia P388 / drug therapy. Leukemia P388 / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / radiotherapy. Male. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / radiotherapy. Meta-Analysis as Topic. Mice. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Rats. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Time Factors. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679253.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Radiation-Sensitizing Agents; 04ZR38536J / oxaliplatin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 71
  •  go-up   go-down






Advertisement